IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment of SO-HDL and OSO-HDL efficiently curtailed CML-induced IL-6 production, apparent from a marked reduction of 8.5% and 4.6% of IHC stained area that accounted for a significant 1.8-fold (p < 0.05) and 3.3-fold lower (p < 0.001) IHC stained area than appeared in the CML injected group.